EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

FKBP5 blockade may provide a new horizon for the treatment of stress‐associated disorders: An in‐silico study

Ali A Asadi-Pooya iD, Mahdi Malekpour, Bardia Zamiri, Mohammad Kashkooli, Negar Firouzabadi

Epilepsia Open · 2023

DOI: 10.1002/epi4.12749 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia Open, 2023. Verfasst von Ali A Asadi-Pooya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Sertraline, Fluoxetine. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shiraz University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We searched for, from the FDA (Food and Drug Administration‐USA)‐approved drugs, inhibitors of FKBP5 with tolerable adverse effect profiles (eg, mild headache, sedation, etc.) and with the ability to cross the blood brain barrier (BBB), using bio‐informatics tools (in‐silico). This may pave the road for designing clinical trials of such drugs in patients with functional seizures (FS) and other stress‐associated disorders.

Methods

Several databases were used to find all the approved drugs that potentially have interactions with FKBP51 protein [ie, CTD gene‐chemical interaction section of FKBP51 protein of Harmonizome of Mayaanlab, DrugCenteral database, PDID (Protein Drug Interaction Database), DGIdb (the Drug Gene Interaction database)]. Other databases were also searched [eg, clinicaltrials.gov ; DRUGBANK (the FASTA format of the FKBP51 protein was imported to the target sequencing section of the database to find the associated drugs), and the STITCH database (to find the related chemical interaction molecules)].

Results

After a comprehensive search of the designated databases, 28 unique and approved drugs were identified. Fluticasone propionate and Mifepristone and Ponatinib, Mirtazapine, Clozapine, Enzalutamide, Sertraline, Prednisolone, Fluoxetine, Dexamethasone, Clomipramine, Duloxetine, Citalopram, Chlorpromazine, Nefazodone, and Escitalopram are inhibitors of FKBP5 and have BBB permeability. Significance While the current in‐silico repurposing study could identify potential drugs (that are already approved and are widely available) for designing clinical trials in patients with stress‐associated disorders (eg, FS), any future clinical trial should consider the pharmacological profile of the desired drug and also the characteristics and comorbidities of the patients in order to foster a success.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SertralineFluoxetineUnited StatesHumansCitalopramClomipramineDuloxetine Hydrochloride

Stichwörter der Autor:innen

PNESdissociativedrugpsychogenicseizure

Substanzen

SertralineFluoxetineCitalopramClomipramineDuloxetine Hydrochloride

Autor:innen und Institutionen

  • Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Department of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

ORCID-Profile: Ali A Asadi-Pooya

Förderung

  • Shiraz University of Medical Sciences

Zitieren

APA

Asadi-Pooya, A. A., Malekpour, M., Zamiri, B., Kashkooli, M., & Firouzabadi, N. (2023). FKBP5 blockade may provide a new horizon for the treatment of stress‐associated disorders: An in‐silico study. Epilepsia Open. https://doi.org/10.1002/epi4.12749

Vancouver

Asadi-Pooya AA, Malekpour M, Zamiri B, Kashkooli M, Firouzabadi N. FKBP5 blockade may provide a new horizon for the treatment of stress‐associated disorders: An in‐silico study. Epilepsia Open. 2023. doi:10.1002/epi4.12749

BibTeX
@article{AsadiPooya2023,
  author = {Asadi-Pooya, Ali A and Malekpour, Mahdi and Zamiri, Bardia and Kashkooli, Mohammad and Firouzabadi, Negar},
  title = {FKBP5 blockade may provide a new horizon for the treatment of stress‐associated disorders: An in‐silico study},
  journal = {Epilepsia Open},
  year = {2023},
  doi = {10.1002/epi4.12749}
}
Kostenlos starten →